Unknown

Dataset Information

0

BRCA1 R1699Q variant displaying ambiguous functional abrogation confers intermediate breast and ovarian cancer risk.


ABSTRACT: Clinical classification of rare sequence changes identified in the breast cancer susceptibility genes BRCA1 and BRCA2 is essential for appropriate genetic counselling of individuals carrying these variants. We previously showed that variant BRCA1 c.5096G>A p.Arg1699Gln in the BRCA1 transcriptional transactivation domain demonstrated equivocal results from a series of functional assays, and proposed that this variant may confer low to moderate risk of cancer.Measures of genetic risk (report of family history, segregation) were assessed for 68 BRCA1 c.5096G>A p.Arg1699Gln (R1699Q) families recruited through family cancer clinics, comparing results with 34 families carrying the previously classified pathogenic BRCA1 c.5095C>T p.Arg1699Trp (R1699W) mutation at the same residue, and to 243 breast cancer families with no BRCA1 pathogenic mutation (BRCA-X).Comparison of BRCA1 carrier prediction scores of probands using the BOADICEA risk prediction tool revealed that BRCA1 c.5096G>A p.Arg1699Gln variant carriers had family histories that were less 'BRCA1-like' than BRCA1 c.5095C>T p.Arg1699Trp mutation carriers (p<0.00001), but more 'BRCA1-like' than BRCA-X families (p=0.0004). Further, modified segregation analysis of the subset of 30 families with additional genotyping showed that BRCA1 c.5096G?>A p.Arg1699Gln had reduced penetrance compared with the average truncating BRCA1 mutation penetrance (p=0.0002), with estimated cumulative risks to age 70 of breast or ovarian cancer of 24%.Our results provide substantial evidence that the BRCA1 c.5096G>A p.Arg1699Gln (R1699Q) variant, demonstrating ambiguous functional deficiency across multiple assays, is associated with intermediate risk of breast and ovarian cancer, highlighting challenges for risk modelling and clinical management of patients of this and other potential moderate-risk variants.

SUBMITTER: Spurdle AB 

PROVIDER: S-EPMC3810416 | biostudies-literature | 2012 Aug

REPOSITORIES: biostudies-literature

altmetric image

Publications

BRCA1 R1699Q variant displaying ambiguous functional abrogation confers intermediate breast and ovarian cancer risk.

Spurdle Amanda B AB   Whiley Phillip J PJ   Thompson Bryony B   Feng Bingjian B   Healey Sue S   Brown Melissa A MA   Pettigrew Christopher C   Van Asperen Christi J CJ   Ausems Margreet G E M MG   Kattentidt-Mouravieva Anna A AA   van den Ouweland Ans M W AM   Lindblom Annika A   Pigg Maritta H MH   Schmutzler Rita K RK   Engel Christoph C   Meindl Alfons A   Caputo Sandrine S   Sinilnikova Olga M OM   Lidereau Rosette R   Couch Fergus J FJ   Guidugli Lucia L   Hansen Thomas van Overeem Tv   Thomassen Mads M   Eccles Diana M DM   Tucker Kathy K   Benitez Javier J   Domchek Susan M SM   Toland Amanda E AE   Van Rensburg Elizabeth J EJ   Wappenschmidt Barbara B   Borg Åke Å   Vreeswijk Maaike P G MP   Goldgar David E DE  

Journal of medical genetics 20120801 8


<h4>Background</h4>Clinical classification of rare sequence changes identified in the breast cancer susceptibility genes BRCA1 and BRCA2 is essential for appropriate genetic counselling of individuals carrying these variants. We previously showed that variant BRCA1 c.5096G>A p.Arg1699Gln in the BRCA1 transcriptional transactivation domain demonstrated equivocal results from a series of functional assays, and proposed that this variant may confer low to moderate risk of cancer.<h4>Methods</h4>Mea  ...[more]

Similar Datasets

| S-EPMC4756649 | biostudies-literature
| S-EPMC3170727 | biostudies-literature
| S-EPMC423239 | biostudies-literature
| S-EPMC7922320 | biostudies-literature
| S-EPMC6822003 | biostudies-literature
| S-EPMC1050723 | biostudies-other